Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Maze Therapeutics, Inc.
MAZE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$30.61
▲ +2.69%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.98 - $53.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 151.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Genetics-driven target discovery platform identifying novel disease mechanisms
- Focus on precision medicine addressing underserved patient populations
- First-mover advantage in APOL1-targeted therapeutics with significant market opportunity
- Experienced management team with deep biopharmaceutical and genomics expertise
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Advancement of MZE829 through Phase II trials with potential for accelerated approval pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+3.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MAZE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 6, 2026
MAY 12, 2026
Reported EPS of -$0.45 vs -$0.58 consensus (+22.0% surprise). Revenue of $20.0M vs $10.6M expected (+88.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+22.0%
Next: Apr 6, 2026
Revenue trend · last 8Q
—
—
—
—
-100%
-100%
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$165.0M
$2.5M
$0
$0
$0
$0
$0
$20.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-121.0%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$64.00
▲ +109.1% vs $30.61
Latest: Truist · $64.00 · Apr 14, 2026
1 analyst covering